Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 3
2010 1
2011 1
2013 4
2014 2
2015 1
2016 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Genet Med. 2011 Jan;13(1):67-76. doi: 10.1097/GIM.0b013e3181fbe46f. Genet Med. 2011. PMID: 21150787
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found adequate evidence to recommend against routine testing for Factor V Leiden (FVL) and/or prothrombin 20210G>A (PT) in the following circumstances: (1 …
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found adequate ev …
Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Genet Med. 2014 Apr;16(4):338-46. doi: 10.1038/gim.2013.141. Epub 2013 Sep 26. Genet Med. 2014. PMID: 24071797 Review.
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found insufficient evidence to recommend prostate cancer antigen 3 (PCA3) testing to inform decisions for when to rebiopsy previously biopsy-negative patient …
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found insufficien …
The EGAPP initiative: lessons learned.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Genet Med. 2014 Mar;16(3):217-24. doi: 10.1038/gim.2013.110. Epub 2013 Aug 8. Genet Med. 2014. PMID: 23928914 Review.
The Evaluation of Genomic Applications in Practice and Prevention Working Group was first convened in 2005 to develop and test evidence-based methods for the evaluation of genomic tests in transition from research to clinical and public health practice. ...In this a …
The Evaluation of Genomic Applications in Practice and Prevention Working Group was first convened in 2005 to develop and test eviden …
Recommendations from the EGAPP Working Group: genomic profiling to assess cardiovascular risk to improve cardiovascular health.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Genet Med. 2010 Dec;12(12):839-43. doi: 10.1097/GIM.0b013e3181f872c0. Genet Med. 2010. PMID: 21042222
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention Working Group (EWG) found insufficient evidence to recommend testing for the 9p21 genetic variant or 57 other variants in 28 genes (listed in ) to assess risk for cardiovascular d …
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention Working Group (EWG) found insufficient …
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21. Genet Med. 2013. PMID: 23429431
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (EWG) found that, for patients with metastatic colorectal cancer (mCRC) who are being considered for treatment with cetuximab or panitumumab, there is convin …
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (EWG) found that, …
Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Genet Med. 2009 Jan;11(1):15-20. doi: 10.1097/GIM.0b013e31818efd9d. Genet Med. 2009. PMID: 19125128 Free PMC article.
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found that the evidence is currently insufficient to recommend for or against the routine use of UGT1A1 genotyping in patients with metastatic colorectal can …
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found that the ev …
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Genet Med. 2009 Jan;11(1):66-73. doi: 10.1097/GIM.0b013e3181928f56. Genet Med. 2009. PMID: 19125125 Free PMC article.
The evidence is insufficient to assess the balance of benefits and harms of the proposed uses of the tests. The EWG encourages further development and evaluation of these technologies. RATIONALE: The measurement of gene expression in breast tumor tissue is proposed as a wa …
The evidence is insufficient to assess the balance of benefits and harms of the proposed uses of the tests. The EWG encourages further devel …
Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Genet Med. 2007 Dec;9(12):819-25. doi: 10.1097/gim.0b013e31815bf9a3. Genet Med. 2007. PMID: 18091431 Free PMC article.
This statement summarizes the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommendations regarding CYP450 genetic testing in adult patients beginning treatment with selective serotonin reuptake inhibitors (SSRIs), and the supporting …
This statement summarizes the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommendations reg …
Recommendations from the EGAPP Working Group: does genomic profiling to assess type 2 diabetes risk improve health outcomes?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group; Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, et al. Genet Med. 2013 Aug;15(8):612-7. doi: 10.1038/gim.2013.9. Epub 2013 Mar 14. Genet Med. 2013. PMID: 23492873
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (EWG) found insufficient evidence to recommend testing for predictive variants in 28 variants (listed in Table 1) to assess risk for type 2 diabetes in the g …
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (EWG) found insuf …
Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Genet Med. 2009 Jan;11(1):35-41. doi: 10.1097/GIM.0b013e31818fa2ff. Genet Med. 2009. PMID: 19125126 Free PMC article.
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found sufficient evidence to recommend offering genetic testing for Lynch syndrome to individuals with newly diagnosed colorectal cancer to reduce morbidity …
SUMMARY OF RECOMMENDATIONS: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found sufficient …
11 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page